Koyfin Home > Directory > Health Care > Acceleron Pharma > Total Debt / EBITDA

Acceleron Pharma Total Debt / EBITDA Chart (XLRN)

Acceleron Pharma annual/quarterly Total Debt / EBITDA from 2012 to 2020.
  • Acceleron Pharma Total Debt / EBITDA for the quarter ending June 06, 2020 was $0m a 58.81% decrease of 0m year over year
  • Acceleron Pharma Total Debt / EBITDA for the last 12 months ending June 06, 2020 was $0m a -16.31% increase of 0m year over year
  • Acceleron Pharma Annual Total Debt / EBITDA for 2019 was $0m a 1,110.18% decrease of -2m from 2018
  • Acceleron Pharma Annual Total Debt / EBITDA for 2013 was $2m a 134.13% increase of 3m from 2012
  • Acceleron Pharma Annual Total Debt / EBITDA for 2012 was $-1m a 119.66% decrease of -1m from 2011
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
  • Acceleron Pharma Total Debt / Equity for the quarter ending December 12, 2013 was $29m
View Chart On Koyfin

Quarterly XLRN Total Debt / EBITDA Data

06/2020$0m
03/2020$0m
12/2019$0m
09/2019$0m
06/2019$0m
03/2019$0m
12/2013$-1m
09/2013$-1m
06/2013$0m
03/2013$2m

Annual XLRN Total Debt / EBITDA Data

2019$0m
2013$2m
2012$-1m
2011$0m